32 related articles for article (PubMed ID: 11051596)
1. Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis.
Matsuoka S; Matsumura H; Nakamura H; Oshiro S; Arakawa Y; Hayashi J; Sekine N; Nirei K; Yamagami H; Ogawa M; Nakajima N; Amaki S; Tanaka N; Moriyama M
J Clin Biochem Nutr; 2009 Nov; 45(3):292-303. PubMed ID: 19902019
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Normalising Serum Zinc Level for Patients with Olfactory Dysfunction and Zinc Deficiency.
Tanaka H; Mori E; Yonezawa N; Sekine R; Nagai M; Tei M; Otori N
ORL J Otorhinolaryngol Relat Spec; 2024; 86(2):73-81. PubMed ID: 38565084
[TBL] [Abstract][Full Text] [Related]
3. Zinc supplementation with polaprezinc was associated with improvements in albumin, prothrombin time activity, and hemoglobin in chronic liver disease.
Abiru S; Kugiyama Y; Suehiro T; Motoyoshi Y; Saeki A; Nagaoka S; Yamasaki K; Komori A; Yatsuhashi H
J Clin Biochem Nutr; 2024 Mar; 74(2):162-168. PubMed ID: 38510683
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of zinc against hepatitis viruses: current status and future prospects.
Kumar S; Ansari S; Narayanan S; Ranjith-Kumar CT; Surjit M
Front Microbiol; 2023; 14():1218654. PubMed ID: 37908540
[TBL] [Abstract][Full Text] [Related]
5. Zinc in Human Health and Infectious Diseases.
Maywald M; Rink L
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551176
[TBL] [Abstract][Full Text] [Related]
6. Safety of zinc l-carnosine as a Novel food pursuant to Regulation (EU) 2015/2283 and the bioavailability of zinc from this source in the context of Directive 2002/46/EC on food supplements.
; Turck D; Bohn T; Castenmiller J; De Henauw S; Hirsch-Ernst KI; Maciuk A; Mangelsdorf I; McArdle HJ; Naska A; Pelaez C; Pentieva K; Siani A; Thies F; Tsabouri S; Vinceti M; Cubadda F; Frenzel T; Heinonen M; Marchelli R; Neuhäuser-Berthold M; Poulsen M; Prieto Maradona M; Schlatter JR; van Loveren H; Roldán-Torres R; Knutsen HK
EFSA J; 2022 Jun; 20(6):e07332. PubMed ID: 35706682
[TBL] [Abstract][Full Text] [Related]
7. The prophylaxis and treatment potential of supplements for COVID-19.
Sahebnasagh A; Saghafi F; Avan R; Khoshi A; Khataminia M; Safdari M; Habtemariam S; Ghaleno HR; Nabavi SM
Eur J Pharmacol; 2020 Nov; 887():173530. PubMed ID: 32882216
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress modulation in hepatitis C virus infected cells.
Lozano-Sepulveda SA; Bryan-Marrugo OL; Cordova-Fletes C; Gutierrez-Ruiz MC; Rivas-Estilla AM
World J Hepatol; 2015 Dec; 7(29):2880-9. PubMed ID: 26692473
[TBL] [Abstract][Full Text] [Related]
9. Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.
O'Connor KS; Parnell G; Patrick E; Ahlenstiel G; Suppiah V; van der Poorten D; Read SA; Leung R; Douglas MW; Yang JY; Stewart GJ; Liddle C; George J; Booth DR
Genes Immun; 2014 Mar; 15(2):88-94. PubMed ID: 24335707
[TBL] [Abstract][Full Text] [Related]
10. The zinc transporter Zip14 influences c-Met phosphorylation and hepatocyte proliferation during liver regeneration in mice.
Aydemir TB; Sitren HS; Cousins RJ
Gastroenterology; 2012 Jun; 142(7):1536-46.e5. PubMed ID: 22374166
[TBL] [Abstract][Full Text] [Related]
11. Zinc and liver disease.
Mohammad MK; Zhou Z; Cave M; Barve A; McClain CJ
Nutr Clin Pract; 2012 Feb; 27(1):8-20. PubMed ID: 22307488
[TBL] [Abstract][Full Text] [Related]
12. Antioxidants as therapeutic agents for liver disease.
Singal AK; Jampana SC; Weinman SA
Liver Int; 2011 Nov; 31(10):1432-48. PubMed ID: 22093324
[TBL] [Abstract][Full Text] [Related]
13. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C.
Ko WS; Guo CH; Yeh MS; Lin LY; Hsu GS; Chen PC; Luo MC; Lin CY
World J Gastroenterol; 2005 Aug; 11(30):4697-702. PubMed ID: 16094713
[TBL] [Abstract][Full Text] [Related]
14. Preliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1b.
Nagamine T; Takagi H; Takayama H; Kojima A; Kakizaki S; Mori M; Nakajima K
Biol Trace Elem Res; 2000; 75(1-3):53-63. PubMed ID: 11051596
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
Suzuki H; Takagi H; Sohara N; Kanda D; Kakizaki S; Sato K; Mori M;
World J Gastroenterol; 2006 Feb; 12(8):1265-9. PubMed ID: 16534882
[TBL] [Abstract][Full Text] [Related]
16. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C.
Takagi H; Nagamine T; Abe T; Takayama H; Sato K; Otsuka T; Kakizaki S; Hashimoto Y; Matsumoto T; Kojima A; Takezawa J; Suzuki K; Sato S; Mori M
J Viral Hepat; 2001 Sep; 8(5):367-71. PubMed ID: 11555194
[TBL] [Abstract][Full Text] [Related]
17. Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin.
Murakami Y; Koyabu T; Kawashima A; Kakibuchi N; Kawakami T; Takaguchi K; Kita K; Okita M
J Nutr Sci Vitaminol (Tokyo); 2007 Jun; 53(3):213-8. PubMed ID: 17874825
[TBL] [Abstract][Full Text] [Related]
18. Utility of polaprezinc in reducing toxicities during radiotherapy: a literature review.
Doi H; Kuribayashi K; Kijima T
Future Oncol; 2018 Aug; 14(19):1977-1988. PubMed ID: 30074413
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
